Johnson & Johnson (NYSE:JNJ) said that data from late-stage studies showed that its oral medication, icotrokinra, was more effective compared with Bristol Myers' (BMY) deucravacitinib (Sotyktu) for moderate to severe plaque psoriasis. The studies found that icotrokinra not only met ...